Bolt Biotherapeutics, Inc., a Redwood City, Calif.-based biotechnology company focused on leveraging the immune system to achieve anti-tumor immunity in patients, completed a $54M Series B financing.
The round was led by Pivotal bioVenture Partners with participation from Nan Fung Life Sciences and existing investors Novo Holdings and Vivo Capital.
The company intends to use the funds to advance its lead coniugate into the clinic as well as to build its pipeline and further develop its technology platform.
Founded by Dr. Ed Engleman, professor of pathology and medicine, Stanford Medicine, Bolt Biotherapeutics develops Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of cancer therapeutics, which, systemically-administered, uncover the immune system to induce anti-tumor immunity.
The company is led by a team with oncology drug discovery and development experience.